Literature DB >> 5287835

The syndrome of myasthenia and polymyositis with comments on therapy.

T R Johns, W J Crowley, J Q Miller, J F Campa.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1971        PMID： 5287835     DOI： 10.1111/j.1749-6632.1971.tb30742.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN： 0077-8923            Impact factor:   5.691


× No keyword cloud information.
  8 in total

1.  Myasthenic decrement and myasthenic myopathy. A study on the effects of thymectomy.

Authors:  P Pinelli; A Arrigo; A Moglia
Journal:  J Neurol Neurosurg Psychiatry       Date:  1975-06       Impact factor: 10.154

2.  A case of myasthenia gravis with neurogenic amyotrophy.

Authors:  S Negri; T Caraceni; F Cornelio
Journal:  Z Neurol       Date:  1973

Review 3.  Recent advances in polymyositis.

Authors:  W M Behan; P O Behan
Journal:  Ital J Neurol Sci       Date:  1984-03

4.  Association of myasthenia gravis and polymyositis with neoplasia, infection and autoimmune disorders.

Authors:  W M Behan; P O Behan; D Doyle
Journal:  Acta Neuropathol       Date:  1982       Impact factor: 17.088

5.  Role of complement in the pathogenesis of experimental autoimmune myasthenia gravis.

Authors:  V A Lennon; M E Seybold; J M Lindstrom; C Cochrane; R Ulevitch
Journal:  J Exp Med       Date:  1978-04-01       Impact factor: 14.307

6.  Autoimmune chronic active hepatitis and polymyositis in a patient with myasthenia gravis and thymoma.

Authors:  K F Ko; T Ho; K W Chan
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-11       Impact factor: 10.154

7.  The perifascicular atrophy factor. An aid in the histological diagnosis of polymyositis.

Authors:  H P Baumli; M Mumenthaler
Journal:  J Neurol       Date:  1977-01-13       Impact factor: 4.849

8.  Voluntary activation failure is detectable in some myositis patients with persisting quadriceps femoris weakness: an observational study.

Authors:  Catherine B Molloy; Ahmed O Al-Omar; Kathryn T Edge; Robert G Cooper
Journal:  Arthritis Res Ther       Date:  2006-04-10       Impact factor: 5.156
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.